Blood cytokines may hold key to predicting vitiligo progression

NCT ID NCT07298551

Not yet recruiting Knowledge-focused Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will measure 12 immune-signaling proteins (cytokines) in the blood of 125 people with vitiligo and healthy volunteers. The goal is to create a model that can predict when the disease will become active and how well a patient will respond to treatment. Currently, doctors rely on visible skin changes, which can be delayed and subjective. This research aims to provide an objective tool to guide earlier and more effective treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that helps doctors predict vitiligo flare-ups and choose the best treatment for each patient.
What could go wrong: This is an early observational study, not a treatment trial. The model may not prove accurate enough for routine use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VITILIGO

Contacts and locations

Locations

Xijing Hospital

Xi'an, Shannxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.